In the 1962-1968 window, research pursued field-based validation of live attenuated vaccines for measles and mumps, emphasizing robust neutralizing antibody responses, practical vaccination regimens, and applicability across varied populations. Comparative studies weighed killed/inactivated vaccines against live vaccines, focusing on antibody persistence, protection following exposure, and booster strategies, while field trial methodologies and standardized surveillance enabled cross-site implementation in diverse settings. Insights into immunoglobulin and passive antibody interactions helped delineate factors that influence observed protection, while booster regimens and post-vaccination antigenic optimization were pursued to sustain immunity. Historical Significance: The period yielded foundational work in establishing field trial methodologies that linked protection to population-level outcomes, shaping later precision vaccinology approaches. It fostered the recognition of live attenuated vaccines as robust, field-proven interventions with clear pathways for booster regimens and antigenic optimization. Collectively, these efforts unified laboratory attenuation science with real-world effectiveness assessments and laid the groundwork for sequencing of measles and mumps vaccine development in subsequent decades.